US EPA

2770702 

Journal Article 

Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin 

Gregorio, F; Ambrosi, F; Manfrini, S; Velussi, M; Carle, F; Testa, R; Merante, D; Filipponi, P 

1999 

Yes 

Diabetic Medicine
ISSN: 0742-3071
EISSN: 1464-5491 

ENGLAND 

16 

12 (December 1999) 

1016-1024 

To assess the effects and safety of increasing sulphonylurea dosages or adding metformin in poorly controlled elderly Type 2 diabetic patients. A 18-month multicentre clinical study was performed on sulphonylurea-treated diabetic patients over 70 years of age with well-preserved renal function, steady fasting blood glucose > or = 200 mg/dl and HbA1c > or = 9%. Patients were randomly assigned to sulphonylurea increased up to its maximum dosage (1st group) or to addition of metformin (2nd group). Glycaemic control, lipid pattern, haemostatic status and safety were monitored during run-in, at baseline and at scheduled intervals for 18 months. Results refer to 85 patients in the 1st group and 89 patients in the 2nd with complete data. Similar improvements in glycaemic levels were observed with both treatments within the first month and a similar decrease in HbA1c within the third month. No further changes occurred in glycaemic control. In the 1st group, fasting glucose (mmol/l, mean +/- SE) decreased from 14.21 +/- 0.49 to 9.88 +/- 0.21, average day-long glucose from 14.87 +/- 0.27 to 10.69 +/- 0.19 and HbAt1c(%) from 10.32 +/- 0.13 to 8.66 +/- 0.13. In the 2nd treatment group fasting glucose decreased from 14.59 +/- 0.61 to 9.05 +/- 37.28, average day-long glucose from 15.09 +/- 0.29 to 10.32 +/- 0.21 and HbA1c from 10.33 +/- 0.13 to 8.77+/-0.12 (for all P 

Cholesterol, HDL; Aging; Male; Blood Glucose; Thrombin; Humans; Hemoglobin A, Glycosylated; Index Medicus; Antithrombin III; Cholesterol, LDL; Female; Fibrinolysis; Gliclazide; Glyburide; Aged; Metformin; Blood Platelets; Hypoglycemic Agents; Diabetes Mellitus, Type 2